Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Pfizer stock | $36.05
Own Pfizer stock in just a few minutes.
Pfizer Inc is a drug manufacturers—general business based in the US. Pfizer shares (PFE) are listed on the NYSE and all prices are listed in US Dollars. Pfizer employs 88,300 staff and has a trailing 12-month revenue of around USD$49.2 billion.
How to buy shares in Pfizer
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Pfizer Find the stock by name or ticker symbol: PFE. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pfizer reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$36.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pfizer, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Pfizer. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- PFE shares summary
- Compare share dealing platforms
- Is PFE stock a buy or sell?
- Stock performance over time
- Can I short PFE shares?
- Is PFE suitable for ethical investing?
- Are PFE shares over-valued?
- Pfizer's financials
- How volatile are PFE shares?
- Does Pfizer pay a dividend?
- Have PFE shares ever split?
- Other common questions
Pfizer share price
Use our graph to track the performance of PFE stocks over time.Pfizer shares at a glance
Information last updated 2020-09-25.
| Latest market close | USD$36.05 |
|---|---|
| 52-week range | USD$27.88 - USD$40.97 |
| 50-day moving average | USD$37.3654 |
| 200-day moving average | USD$35.7774 |
| Wall St. target price | USD$41.79 |
| PE ratio | 14.2292 |
| Dividend yield | USD$1.52 (4.22%) |
| Earnings per share (TTM) | USD$2.526 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Pfizer stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pfizer price performance over time
Historical closes compared with the close of $36.05 from 2020-09-25
| 1 week (2020-09-22) | -0.55% |
|---|---|
| 1 month (2020-08-28) | -4.91% |
| 3 months (2020-06-29) | 10.45% |
| 6 months (2020-03-27) | 16.67% |
| 1 year (2019-09-27) | -0.47% |
|---|---|
| 2 years (2018-09-28) | -18.20% |
| 3 years (2017-09-29) | 0.98% |
| 5 years (2015-09-29) | 16.22% |
Is Pfizer under- or over-valued?
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's P/E ratio
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Pfizer shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pfizer's PEG ratio
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3603. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.1 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
Pfizer financials
| Revenue TTM | USD$49.2 billion |
|---|---|
| Operating margin TTM | 29.82% |
| Gross profit TTM | USD$41.7 billion |
| Return on assets TTM | 5.49% |
| Return on equity TTM | 22.81% |
| Profit margin | 28.81% |
| Book value | $11.584 |
| Market capitalisation | USD$198.7 billion |
TTM: trailing 12 months
Shorting Pfizer shares
There are currently 45.2 million Pfizer shares held short by investors – that's known as Pfizer's "short interest". This figure is 15.5% down from 53.5 million last month.
There are a few different ways that this level of interest in shorting Pfizer shares can be evaluated.
Pfizer's "short interest ratio" (SIR)
Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer shares currently shorted divided by the average quantity of Pfizer shares traded daily (recently around 21.5 million). Pfizer's SIR currently stands at 2.1. In other words for every 100,000 Pfizer shares traded daily on the market, roughly 2100 shares are currently held short.
However Pfizer's short interest can also be evaluated against the total number of Pfizer shares, or, against the total number of tradable Pfizer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pfizer shares in existence, roughly 10 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Pfizer shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfizer.
Find out more about how you can short Pfizer stock.
Pfizer's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Pfizer's total ESG risk score
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 08/01/2020) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Pfizer's environmental score
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Pfizer's social score
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Pfizer's governance score
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Pfizer's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Pfizer Inc was last rated for ESG on: 2020-08-01.
| Total ESG score | 33.15 |
|---|---|
| Total ESG percentile | 60.54 |
| Environmental score | 7 |
| Environmental score percentile | 6 |
| Social score | 18.47 |
| Social score percentile | 6 |
| Governance score | 13.68 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
Pfizer share dividends
Dividend payout ratio: 58.5% of net profits
Recently Pfizer has paid out, on average, around 58.5% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.22% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 4.22% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.52 per share.
Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Pfizer's most recent dividend payout was on 1 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 30 July 2020 (the "ex-dividend date").
Have Pfizer's shares ever split?
Pfizer's shares were split on a 3:1 basis on 1 July 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Pfizer share price volatility
Over the last 12 months, Pfizer's shares have ranged in value from as little as $27.88 up to $40.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.6589. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer overview
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Frequently asked questions
Ask an Expert